Cumulative OR rate (%) in relation to treatment duration and tumor site in B-CLL patients who responded to alemtuzumab therapy
| Tumor site . | Proportion (%) of responding patients . | ||
|---|---|---|---|
| Wk 6 . | Wk 12 . | Wk 18 . | |
| Blood, n = 37 | 1004-150 | 100 | 100 |
| Bone marrow, n = 30 | 10 | 45 | 100 |
| Lymph nodes, n = 27 | 42 | 69 | 100 |
| Spleen, n = 25 | 29 | 54 | 100 |
| Tumor site . | Proportion (%) of responding patients . | ||
|---|---|---|---|
| Wk 6 . | Wk 12 . | Wk 18 . | |
| Blood, n = 37 | 1004-150 | 100 | 100 |
| Bone marrow, n = 30 | 10 | 45 | 100 |
| Lymph nodes, n = 27 | 42 | 69 | 100 |
| Spleen, n = 25 | 29 | 54 | 100 |
Median time to CR in blood was 21 days (range, 7-63 days).